Health Care Equipment

Conmed

Conmed released FY2026 Q1 earnings on April 29 After-Market EST, actual revenue USD 317.05 M (forecast USD 310.61 M), actual EPS USD 0.45 (forecast USD 0.695)

Conmed to Release FY2026 Q1 Earnings on April 29 After-Market EST, Forecast Revenue USD 310.59 M, EPS USD 0.695

Conmed released FY2025 Q4 earnings on January 28 After-Market EST, actual revenue USD 373.2 M (forecast USD 366.88 M), actual EPS USD 0.5405 (forecast USD 1.26)

Conmed released FY2025 annual earnings on January 28 After-Market EST, actual revenue USD 1.375 B (forecast USD 1.368 B), actual EPS USD 1.51 (forecast USD 3.085)

Conmed to Release FY2025 Q4 Earnings on January 28 After-Market EST, Forecast Revenue USD 366.88 M, EPS USD 1.26

Conmed released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 337.93 M (forecast USD 334.76 M), actual EPS USD 0.09 (forecast USD 0.875)

Conmed released FY2025 9 Months Earnings on November 5 After-Market EST, with actual revenue of USD 1.002 B and EPS of USD 0.97

Conmed to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 334.76 M, EPS USD 0.875

CONMED's EVP Disposes of Company Common Stock

Conmed released FY2025 Semi-Annual earnings on July 31 After-Market EST, actual revenue USD 663.6 M, actual EPS USD 0.88

Conmed released FY2025 Q2 earnings on July 30 After-Market EST, actual revenue USD 342.35 M (forecast USD 338.42 M), actual EPS USD 0.69 (forecast USD 0.95)

Conmed to release FY2025 Q2 earnings on July 30 After-Market EST, forecast revenue USD 338.42 M, EPS USD 0.95

CONMED's rating downgraded with target price at $62.20

Kangmei Company Extends Credit Agreement Maturity to June 10, 2030

Needham Downgrades Conmed to Hold

Konmin Announces Quarterly Dividend of $0.20 Per Share

Kangmei Convenes Annual Shareholders' Meeting to Elect Directors

Kangmei Appoints LaVerne Council as New Independent Board Chair

Kangmei Company Submits Stephan Epinette Beneficial Ownership Declaration

CONMED stock rating downgraded to 'hold'

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

MetaVia

Rubico

Virax Biolabs

OceanPal

CNMD

Wall Street Zen downgraded CONMED (NYSE:CNMD) from a "strong-buy" to a "buy" rating. Other firms have also adjusted their ratings, with Zacks upgrading to "hold" and Wells Fargo lowering the target price from $42 to $39. Currently, CONMED has a consensus rating of "Reduce" and a target price of $46.20. The stock opened at $36.72, with a market cap of $1.11 billion. Recent earnings showed $0.89 EPS, beating estimates, but revenue declined 1.3% year-over-year. Analysts forecast 4.37 EPS for the fiscal year.

Market Beat

CONMED (NYSE:CNMD) Stock Rating Lowered by Wall Street Zen

CONMED (CNMD) reported Q1 2026 revenue of $317 million and EPS of $0.45, reflecting a decline in net margin to 4% from 9% a year prior. Analysts forecast earnings growth of 30.8% annually, relying on operational improvements to enhance profitability. However, concerns arise from a $26 million one-off loss and high debt levels, which could hinder margin recovery. Investors are divided, with bulls optimistic about future margin improvements and bears cautious due to potential revenue growth challenges and rising costs.

Simplywall

CONMED (CNMD) Q1 Margin Compression To 4% Tests Bullish Earnings Growth Narrative

CONMED Corp reported Q1 2026 revenue of $317M, a slight decrease from $321.3M in Q1 2025. Net income rose to $13.8M, up 129% year-over-year, with diluted EPS increasing to $0.45, a 137% rise. Orthopedic sales grew 6.8%, offsetting declines from the exit of gastroenterology product lines. Recurring single-use products accounted for 85% of revenue, contributing to improved gross margins, which expanded by 260 basis points. The company continues to optimize its supply chain following the strategic exit from gastroenterology.

TradingView

CONMED Corp 1Q 2026: Revenue $317M, EPS $0.45— 10-Q Summary

Wall Street Zen upgraded CONMED (NYSE:CNMD) from a "buy" to a "strong-buy" rating. The stock has seen mixed ratings from other analysts, with Needham maintaining a "hold" and Weiss Ratings giving a "sell". CONMED's current stock price is $38.47, with a market cap of $1.16 billion. The company reported earnings of $1.43 per share, exceeding estimates, and a revenue increase of 7.9% year-over-year. Analysts predict an EPS of 4.35 for the current fiscal year.

CONMED (NYSE:CNMD) Upgraded to Strong-Buy at Wall Street Zen

CONMED Corp (CNMD) shares have entered oversold territory with a Relative Strength Index (RSI) of 29.4, indicating potential buying opportunities as heavy selling may be exhausting. The stock traded as low as $33.85, with a 52-week range of $33.21 to $61.08. In comparison, the S&P 500 ETF (SPY) has an RSI of 47.6. Investors may consider this RSI reading as a signal to look for entry points in CNMD shares.

nasdaq

RSI Alert: CONMED (CNMD) Now Oversold

Kempner Capital Management Inc. significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 87.4% in Q4, now holding 6,258 shares valued at $252,000. Other hedge funds have also adjusted their positions, with notable increases from Tributary Capital Management and SG Americas Securities. CONMED's stock opened at $36.51, with a market cap of $1.13 billion and a PE ratio of 24.18. Analysts have mixed ratings on the stock, with a consensus rating of "Reduce" and an average price target of $50.17.

CONMED Corporation $CNMD Shares Sold by Kempner Capital Management Inc.

SBIO

CONMED's share price has dropped 39.3% over the past year, currently trading at $35.94. Recent analysis suggests the stock is undervalued, with a Discounted Cash Flow (DCF) model estimating an intrinsic value of $88.46 per share, indicating a 59.4% discount. Additionally, CONMED's P/E ratio of 23.6x is below the industry average of 26.9x, further suggesting it may be undervalued. Investors are encouraged to consider different valuation methods and narratives to assess the stock's potential.

ALPS Medical Breakthrough

Is It Time To Reassess CONMED (CNMD) After A 39% One Year Share Price Slide

Conmed(CNMD.US)